Ondokuz Mayis University, Faculty of Medicine, Department of Radiology, Samsun, Turkey.
Ondokuz Mayis University, Faculty of Medicine, Department of Infectious Disease and Clinical Microbiology, Samsun, Turkey.
Rev Inst Med Trop Sao Paulo. 2021 Jun 25;63:e51. doi: 10.1590/S1678-9946202163051. eCollection 2021.
In December 2019, several cases of pneumonia of unknown origin were reported in the city of Wuhan, province of Hubei, China. The pathogen was named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease was named coronavirus disease 2019 (COVID-19). Acute phase reactans (APRs) are critical in the early diagnosis, treatment, and for monitoring the progression of COVID-19. Seventy two patients were included in the study and infections confirmed by real-time reverse transcription polymerase chain reaction. Clinical parameters, the level of APFs and D-dimer were assessed and results were retrived from the patients' medical records. Chest computed tomography (CT) findings were described for each patient and they were divided into two groups, with or without COVID-19 pneumonia. The correlation between APRs and CT findings and the patients' prognosis were evaluated. Twenty eight (38.8%) of the 72 patients were female and 44 (61.2%) were male. The most common symptom was cough (43%) and the most common associated chronic disease was hypertension (12.5%). Thirty (41.6%) patients had completely normal chest CT, while 42 (58.4%) patients had typical findings in terms of COVID-19 pneumonia. C reactive protein (CRP), lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), ferritin, procalcitonin and D-Dimer levels were statistically significantly higher in patients with pneumonia than in those without pneumonia and these parameters were also statistically significantly higher in patients with severe illness. In conclusion, CRP, LDH, ESR, ferritin, and D-Dimer were associated with severe COVID-19 pneumonia. These biomarkers can be used to evaluate the prognosis to predict the clinical course of disease, allowing a proper management and treatment of the patients.
2019 年 12 月，中国湖北省武汉市报告了几例不明原因肺炎病例。病原体被命名为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），该疾病被命名为 2019 年冠状病毒病（COVID-19）。急性相反应物（APRs）在 COVID-19 的早期诊断、治疗和监测疾病进展中至关重要。本研究纳入了 72 例患者，这些患者的感染均通过实时逆转录聚合酶链反应得到确认。评估了临床参数、APFs 和 D-二聚体的水平，并从患者的病历中检索了结果。对每位患者的胸部计算机断层扫描（CT）结果进行了描述，并将他们分为伴有或不伴有 COVID-19 肺炎的两组。评估了 APRs 与 CT 结果以及患者预后之间的相关性。72 例患者中，28 例（38.8%）为女性，44 例（61.2%）为男性。最常见的症状是咳嗽（43%），最常见的合并慢性疾病是高血压（12.5%）。30 例（41.6%）患者的胸部 CT 完全正常，而 42 例（58.4%）患者的胸部 CT 有 COVID-19 肺炎的典型表现。与无肺炎患者相比，肺炎患者的 C 反应蛋白（CRP）、乳酸脱氢酶（LDH）、红细胞沉降率（ESR）、铁蛋白、降钙素原和 D-二聚体水平显著升高，且重症患者的这些参数也显著升高。总之，CRP、LDH、ESR、铁蛋白和 D-二聚体与严重 COVID-19 肺炎有关。这些生物标志物可用于评估预后，以预测疾病的临床过程，从而对患者进行适当的管理和治疗。
